Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Monday, November 11, 2024, at 10:00 a.m. ET in Boston, MA.

A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trials in myositis, systemic lupus erythematosus, systemic sclerosis, generalized myasthenia gravis and in the RESET-PV™ sub-study within the DesCAARTes™ clinical trial in pemphigus vulgaris, along with the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

William Gramig
Precision AQ
william.gramig@precisionaq.com

Staff

Recent Posts

Global Orthodontists Gather in China to Explore Smartee’s Mandibular Repositioning Technology

XI'AN, China , June 26, 2025 /PRNewswire/ -- Smartee Denti-Technology recently hosted international orthodontic experts and…

2 hours ago

Kentro Earns 2025 Washington Post Top Workplaces Award for Second Consecutive Year

MCLEAN, Va., June 25, 2025 /PRNewswire/ -- IT Concepts, Inc. DBA Kentro (Kentro hereafter). Kentro…

2 hours ago

Public Advisory – Buying health products online? Know the risks

OTTAWA, ON, June 25, 2025 /CNW/ - Summary Product: Unauthorized health products, including drugs, natural…

2 hours ago

Scott McGohan Launches Mental Health Engagement Catalyst One Morning with Vital Brand-Development Support from Hyperquake

DAYTON, Ohio and CINCINNATI, June 25, 2025 /PRNewswire/ -- Independent creative strategy, branding, and experience…

2 hours ago

Smart Data Solutions and Basys.ai Partner to Empower Health Plans and TPAs with AI-Driven Prior Authorization Solutions

EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Smart Data Solutions (SDS), a leader in healthcare…

2 hours ago